Please use this identifier to cite or link to this item: https://hdl.handle.net/1/543
Title: FIND-CKD: A Randomized Trial of Intravenous Ferric Carboxymaltose Versus Oral Iron in Patients with Chronic Kidney Disease and Iron Deficiency Anaemia.
Authors: MacDougall, I.C.;Bock, Andreas ;Carrera, Fernando ;Eckardt, Kai-Uwe ;Gaillard, Carlo ;Van Wyck, David ;Roubert, Bernard ;Nolen, Jacqueline ;Roger, Simon D 
Issue Date: Nov-2014
Source: Volume 29, Issue 11, pp. 2075 - 2084
Journal title: Nephrology Dialysis Transplant
Abstract: Background The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. Methods Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with non-dialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400–600 µg/L) or lower (100–200 µg/L) ferritin or oral iron therapy. The primary end point was time to initiation of other anaemia management (ESA, other iron therapy or blood transfusion) or haemoglobin (Hb) trigger of two consecutive values <10 g/dL during Weeks 8–52. Results The primary end point occurred in 36 patients (23.5%), 49 patients (32.2%) and 98 patients (31.8%) in the high-ferritin FCM, low-ferritin FCM and oral iron groups, respectively [hazard ratio (HR): 0.65; 95% confidence interval (CI): 0.44–0.95; P = 0.026 for high-ferritin FCM versus oral iron]. The increase in Hb was greater with high-ferritin FCM versus oral iron (P = 0.014) and a greater proportion of patients achieved an Hb increase ≥1 g/dL with high-ferritin FCM versus oral iron (HR: 2.04; 95% CI: 1.52–2.72; P < 0.001). Rates of adverse events and serious adverse events were similar in all groups. Conclusions Compared with oral iron, IV FCM targeting a ferritin of 400–600 µg/L quickly reached and maintained Hb level, and delayed and/or reduced the need for other anaemia management including ESAs. Within the limitations of this trial, no renal toxicity was observed, with no difference in cardiovascular or infectious events. ClinicalTrials.gov number NCT00994318.
Description: Open Access: http://ndt.oxfordjournals.org/content/29/11/2075.abstract
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/543
DOI: 10.1093/ndt/gfu201
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/24891437
ISSN: 1460-2385
Publicaton type: Journal Article
Keywords: Kidney Disease
Dialysis
Anaemia
Anemia
Haematology
Hematology
Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Renal Medicine

Show full item record

Page view(s)

2
checked on Feb 1, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.